Revenue, 2025

USD 5.84 Billion

Forecast, 2035

USD 11.38 Billion

CAGR, 2026-2035

5.14%

Report Coverage

Global

Laboratory Animal Medicine Market Key Takeaways

• The laboratory animal medicine market to crossed USD 6.24 billion by 2026.
• Market projected at USD 11.38 billion by 2035.
• CAGR of 5.14% expected in between 2026 to 2035.
• The North America laboratory animal medicine market is projected to grow from USD 2.39 billion in 2025 to USD 4.57 billion by 2035, registering a 6.7% CAGR during the forecast period.
• North America led with a 41% share of the market in 2025.
• Asia Pacific held a 23% share in 2025 & is expected to be the fastest-growing region at the 8.3% CAGR in the studied years. 
• By animal type, the rodents segment captured a major share of 58% of the market in 2025.
• By animal type, the non-human primates segment accounted for a 9% share in 2025 & is expected to grow rapidly at the 7.8% CAGR during 2026-2035.
• By product, the pharmaceuticals segment dominated with a 34% share of the laboratory animal medicine market in 2025.
• By product, the diagnostic kits segment held a 12% share in 2025 & is expected to grow fastest at the 8.1% CAGR in the coming years. 
• By service, the veterinary care services segment captured the largest share of 32% of the market in 2025.
• By service, the diagnostic services segment held a 24% share in 2025 & is expected to witness rapid expansion at the 8.0% CAGR during the forecast period. 
• By application, the drug discovery & development segment led with a 38% share of the market in 2025.
• By application, the genetic research segment accounted for a 10% share in 2025 & is expected to grow at the 8.4% CAGR in the studied years.
• By end user, the pharmaceutical & biotechnology companies segment dominated with a 42% share of the market in 2025.
• By end user, the contract research organizations (CROs) segment captured a 24% share in 2025 & is expected to grow rapidly at the 8.2% CAGR in the upcoming years. 

Laboratory Animal Medicine Market Trends for 2026

The laboratory animal medicine market size was estimated at USD 5.84 billion in 2025 and is predicted to increase from USD 6.24 billion in 2026 to approximately USD 11.38 billion by 2035, expanding at a CAGR of 5.14% from 2026 to 2035.

The laboratory animal medicine market is growing, as these medicines plays significant role in research for different disciplines such as toxicology, pharmacology, and physiology.

Market Overview: What is the Laboratory Animal Medicine Market?

The laboratory animal medicine market is increasing because this type of medicine is an increasing field of veterinary practice that emphasizes animal wellbeing and improvement of research animal health care. The applications of animals as experimental models remain a vital tool in the immediate future, enabling innovative and increasingly molecular discoveries of basic science to be translated into developments in health care for humans and animals alike. The laboratory animal medicines play an important role in the research community and society by managing and supporting the safeguarding of animals in research. Laboratory animal medicine is an exciting discipline that encompasses numerous fields that relate to the use of animals in teaching, research, and testing involving ethology, welfare, biology, genetics, biosafety, physiology, regulatory affairs, toxicology, and animal model advancement.

How is AI Governing the Laboratory Animal Medicine Market?

Integration of AI-driven technology in laboratory animal medicine drives market growth, as AI-driven technology has huge potential to play various roles in veterinary practice, enhancing the way veterinary care is delivered, enhancing results for animals, and eventually humans. The evolution of AI-based technology has led to a novel direction in biomedical research, particularly in translational research with massive potential, promising to transform science. AI is renovating science by lowering the requirement for animal testing and providing more ethical and humane substitutes. AI, in integration with organ-on-a-chip (OoC) and computer simulations, is allowing the advancement of animal digital twins, permitting scientists to predict biological technology.

Future Outlook & Trends in the Laboratory Animal Medicine Market

• Rise of In Vitro and Computational Alternatives: Bioinformatics has been evolving as a promising alternative to animal use and in vitro experiments, as it enables the investigation of biological phenomena using computational tools and biological databases.
• Increased Focus on Refinement: Refinement improves animal welfare by enhancing housing, handling, and investigational technology to reduce distress and pain. Refinements include non-invasive monitoring, efficient use of analgesia, and enrichment to help animals’ psychological and physical well-being.
• Genetically Modified Models: Genetically engineered models are more faithful than traditional models in terms of cancer advancement in humans and bypass a range of limitations of traditional models.

Key Indicators and Highlights

Segmentation Analysis

Animal Type Insights

The Rodents Segment Led the Market in 2025

In 2025, the rodents segment dominated with a 58% of the laboratory animal medicine market. Rodents include their ease of maintenance, small size, limited life cycle, and massive genetic resources. Basic biomedical research covers the description of genes/proteins, the research of anatomical and physiological functions, & the characterization of normal and pathological situations in a diversity of animal species. Rodents are indispensable in biomedical research because of their physiological and genetic resemblances to humans, allowing in considerate diseases, advanced therapies, & safeguarding safety in drug testing.

The rabbits segment held the second-largest share of a 10% in 2025, due to the growing antibody production demand. Ongoing expansion of immunology studies & higher physiological relevance are driving the adoption of rabbits. Alongside, rabbits have a pivotal role in the study of pyrogen and toxicity testing before human trials.

The non-human primates segment held a 9% share in 2025 & is predicted to expand at the 7.8% CAGR in the laboratory animal medicine market. As NHPs have over 93% DNA homology with humans, they are employed in the critical need for complex translational models in infectious disease, neuroscience & immunology. However, several pharmaceutical firms are highly outsourcing their NHP preclinical studies to specialized CROs to guide complex compliance, ethics, & breeding infrastructure.

The dogs segment held a lucrative share of 6% in 2025, due to the surging importance of toxicology & safety testing. Moreover, dogs have a major role in cardiovascular studies, hemophilia research, & oncology, like studying spontaneous lymphoma and cancer treatments.

Product Insights

The Pharmaceuticals Segment Dominated the Market in 2025

The pharmaceuticals segment led with a 34% share of the laboratory animal medicine market in 2025. A rise in disease management needs and expanded laboratory animal welfare standards are fueling the growth of pharmaceuticals. The globally surging disease surveillance & maintenance of pathogen-free animal colonies drive the need for continuous veterinary pharmaceutical & diagnostic interventions.

In 2025, the feed & nutrition segment held the second-largest share of a 22% of the market. The segmental growth is propelled by a rising precision nutrition demand, and advancing research reproducibility necessitates standardized diets. Participation of Institutional Animal Care and Use Committees (IACUC) & similar global agencies demands comprehensive traceability of nutritional ingredients.

The vaccines segment accounted for a 15% share of the laboratory animal medicine market, due to the enforcement of biosecurity programs that increase vaccination. Alongside, accelerating focus on infection prevention & elevating the shift towards recombinant, DNA, and viral-vector vaccines, fosters the progression of vaccines.

On the other hand, the diagnostic kits segment captured a 12% share in 2025 & is estimated to grow at the 8.1% CAGR in the coming era. Respective expansion is fueled by the surging importance of rapid pathogen detection, the development of genetic monitoring, & broadening automation that enhances laboratory efficiency. Integrated digital & AI-enabled analysis, with molecular diagnostic kits, rises testing accuracy, sensitivity, & efficacy.

Service Insights

The Veterinary Care Services Segment Was Dominant in the Market in 2025

The veterinary care services segment led with a 32% share of the market in 2025. Rising requirement for continuous health monitoring, empowerment of compliance standards, & rising investments in animal welfare drive the dominance of veterinary care services. Moreover, a rise in the need for the detection of subclinical pathogens & ensure continuous health monitoring is developing a robust demand for clinical pathology, microbiology, & molecular diagnostics to maintain colony integrity.

The diagnostic services segment captured a 24% share in 2025 & is anticipated to expand fastest at the 8.0% CAGR in the laboratory animal medicine market. Enforcement of extensive health monitoring, genetic quality assurance, & disease screening for lab animals demands advanced diagnostic services. Substantial growth in complex preclinical studies, like gene therapy, targeted oncology, is spurring highly specialized, precise diagnostic assays & pathology services.

The breeding services segment held a 18% share in 2025, due to increasing demand for genetically defined animals. Surging research pipelines & expansion of specialized breeding programs across the globe are driving these kinds of services. Consistent investments in infectious disease research & immunology pipelines are also boosting demand for breeding services.

The quarantine & biosecurity services segment captured a 15% share of the laboratory animal medicine market. Expanded awareness about global health security needs strong isolation & quarantine protocols. Besides this, in this era, government agencies are enforcing comprehensive biosecurity & quarantine mandates to ensure humane treatment & mitigate disease outbreaks.

Application Insights

The Drug Discovery & Development Segment Dominated the Market in 2025

In 2025, the drug discovery & development segment held a major share of 38% of the market. Stringent regulatory requirements for preclinical safety testing, & progression of Genetically Engineered Mouse Models (GEMs) mimics complex human concerns, fostering the respective application. The worldwide rising investments in biologics and targeted immunotherapies need complex in vivo platforms to record pharmacokinetics (PK) & pharmacodynamics (PD) accurately.

The biomedical research segment held the second-largest share of a 28% of the market in 2025. The segmental growth is driven by an accelerated disease burden, which stimulates studies. In addition, ongoing development in precision medicine research, coupled with funding that pushes translational science.

In 2025, the vaccine development segment captured a notable share of 12% of the laboratory animal medicine market. Day by day, emerging infectious diseases are fueling investment. Alongside, advanced vaccine platforms are boosting testing. However, massive public health initiatives are supporting the overall research activities for the vaccine.

The genetic research segment held a 10% share in 2025 & is predicted to expand at the 8.4% CAGR. The emergence of the latest CRISPR technology has significantly lowered the expenditure, time, & complexity of developing genetically modified animal models. Strict guidelines for laboratory animal genetics are propelling the need for continuous, genetically monitored, & rigorously controlled transgenic colonies.

End User Insights

The Pharmaceutical & Biotechnology Companies Segment Led the Market in 2025

In 2025, the pharmaceutical & biotechnology companies segment captured a dominant share of 42% of the market. Animal pharmaceutical companies play a vital role in safeguarding & optimizing the inclusive health of both livestock and pets via the development and distribution of pharma veterinary products. This invention range spans a diversity of interventions, like antibiotics, vaccines, antiparasitics, and nutritional supplements. Companies play a significant role in disease prevention policies. Vaccination programs are industrialized by animal pharmaceutical organizations.

Moreover, the contract research organizations (CROs) segment held a 24% share in 2025 & is estimated to expand at the 8.2% CAGR in the laboratory animal medicine market. Outsourcing preclinical studies offers access to dedicated expertise, advanced technologies, and affordable services, leading to rapid project timelines and enhanced compliance with government standards. CROs are familiar with the government requirements, supporting organizations in navigating compliance requirements efficiently and reducing the challenges of government issues throughout submission processes.

The academic & research institutes segment held a 18% share in 2025, due to the escalating public funding that supports projects. These institutes are promoting collaborative programs, along with the expansion of translational research activity. These institutes are acting as centres for academic training & spurring education for laboratory animal veterinarians.

Whereas government research organizations segment held a 10% share in 2025, due to national health initiatives driving studies. These organizations are promoting disease surveillance programs, along with continuous strategic research investments. Although the emergence of state-sponsored diagnostic networks to track zoonotic diseases & assess vaccines fuels continuous veterinary oversight & diagnostic reagents.

Regional Insights

How did North America dominate the Market in 2025?

In 2025, North America registered dominance with a 41% share of the laboratory animal medicine market due to its advanced pharmaceutical and academic research ecosystem. Spending in medical care innovation is increasing contributions to the American economy and solidifying the nation's role as a leader in healthcare innovation.  A strong presence of major pharmaceutical companies and specialized contract research organizations (CROs) such as Charles River Laboratories drives demand and invention in in-vivo models, which contributes to the growth of the market.

North America Laboratory Animal Medicine Market Growth

The North America laboratory animal medicine market size was estimated at USD 2.39 billion in 2025 and is predicted to increase from USD 2.55 billion in 2026 to approximately USD 4.57 billion by 2035, expanding at a CAGR of 6.7% from 2026 to 2035.

For Instance,

• In November 2025, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) had granted approval of KOMZIFTI for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 alteration who have no satisfactory substitute treatment selections.

U.S. Market Trends

The U.S. contributed a major share of 85% of the market in 2025. In the U.S., the National Institutes of Health (NIH) is accepting a novel initiative to expand innovative, human-driven science while lowering animal use in research, making the U.S. the worldwide center for biomedical innovations. This region established strict ethical strategies and accreditation systems, such as AAALAC International, which was originally established as the American Association for the Accreditation of Laboratory Animal Care, which endorses the humane treatment of animals in science via voluntary assessment and accreditation.

Canada Market Trends 

Canada captured a 10% share of the laboratory animal medicine market in 2025. Ongoing developments are impelled by strict biomedical research funding, rigorous animal welfare laws, and a rise in demand for tailored medicine. Besides this, the Canadian Council on Animal Care (CCAC) is mandating higher standards of care, routine health monitoring, & pain management for research animals.

Asia Pacific: Increasing Healthcare Capabilities

Asia Pacific held a 23% share in 2025, & is anticipated to witness rapid growth at the 8.3% CAGR during 2026-2035. Asia Pacific is expected to see rapid growth in the laboratory animal medicine market, driven by a worldwide hub for biomedical and pharmaceutical research, with China, Japan, and India leading in the advancement of sophisticated, standardized animal services. Due to advancements in biodiversity, experiencing rapid land-use modification, the region has seen extensive habitat loss, increasing human-wildlife integration, and high levels of unregulated wildlife trade, which drives the growth of the market.

China Market Trends

China held a 34% share of the laboratory animal medicine market, & is estimated to expand at the 9.00% CAGR. Key drivers include massive investments by both domestic and international companies into clinical research, oncology, & pharmacology. The progressive CRO sector and local drug development are highly supporting rising chronic disease cases in China.

India Market Trends

India accounted for a 14% share in 2025 & is predicted to expand rapidly at 9.3% CAGR in the laboratory animal medicine market.  India has more than 2300 animal services registered with CPCSEA for leading experiments using animals.  India is transitioning from traditional animal-based to advanced human-relevant technology, such as AI and organoids. This transformation aims to enhance drug achievement rates and establish India as a worldwide revolution hub. India's bio-pharmaceutical industry, ranked third worldwide in terms of volume, is the major supplier of generic drugs worldwide and an advocate of advanced-quality.

Europe: Advancement in Technology

Europe accounted for a lucrative share of 27% in 2025 & is estimated to expand notably at a 6.40% CAGR. Europe is growing significantly in the laboratory animal medicine market, as EU legislation is unique, as it sets a concluding aim of full replacement of animal applications for scientific and educational purposes, and is taking concrete action towards that goal. EU strategies have led to efforts to enhanced enforcement of legislation and to the spending of significant research on animal welfare by the European Commission. Encouraging high standards of laboratory animal medicine via scientific inquiry, which contributes to the growth of the market.

Germany Market Trends

In 2025, Germany captured a 23% share & is predicted to expand at 6.30$ CAGR in the laboratory animal medicine market. A prominent catalyst is the strong adherence of Germany to European Union regulations, like Directive 2010/63/EU & stricter local German Animal Welfare laws that mandate high standards of veterinary care, pain management, & living conditions for all research animals. Local firms, like Boehringer Ingelheim, Bayer, & Merck, are propelling continuous demand for laboratory animal models, preventive medicines, & veterinary therapeutics.

Netherlands Market Trends

The Netherlands held a 7% share in 2025 and is predicted to expand at 6.7% CAGR in the coming era. Especially, the Dutch government is actively fueling a shift away from animal testing in favor of in vitro methods, organ-on-a-chip, & advanced computational models. This nation is known for vast life science hubs, pharmaceutical leaders, & research institutions, such as the Hubrecht Institute & Netherlands Cancer Institute (NKI). 

Market Ecosystem Analysis

Value Chain Analysis

R&D

• Research and Development (R&D) in laboratory animal medicine includes a systematic technology of scientific investigation to advance animal health, enhance diagnostic abilities, and develop novel treatments.
• Key Players: American College of Laboratory Animal Medicine (ACLAM) and AALAS

Manufacturing Processes

• Manufacturing processes in laboratory animal medicine include an integration of extremely regulated pharmaceutical production for animal health products and specialized technology for the care, maintenance, and experimental operation of research animals.
• Key Players: ICLAS (International Council for Laboratory Animal Science)

Patient Services

• Patient services in laboratory animal medicine refer to the inclusive veterinary medical care, health surveillance, and support provided to animals used in biomedical studies, testing, and awareness.
• Key Players: ILAR (Institute for Laboratory Animal Research)

Latest Updates of Key Players in the Laboratory Animal Medicine Market

Market Share Influence Assessment

Competitive Landscape

SWOT Analysis

Strengths

• Laboratory animal medicine provides priceless insights into human disease mechanisms, preventative and therapeutic targets, and management strategies, making them significant tools for translational research.
• Researchers use animals to study more related health challenges that affect both humans and animals, and to ensure the safety of novel healthcare management.

Weaknesses

• Investigational animals are virtually tortured to death, and these tests are done in the interest of human welfare, deprived of any knowledge of how the animals are treated.

Opportunities

• Modern animal models for biomedical research continue to be far improved than substitutes. They are used alongside novel computational technologies and human-driven models.
• Use of pre-emptive analgesics significantly lowers the required concentration of anesthetic gases, ensuing in minimization of respiratory and cardiovascular depression secondary to volatile anesthetics and a rapid recovery from anaesthesia.

Threats

• Animal models often do not precisely replicate human biology, resulting in unreliable information.
• Animal studies are costly, need specialized staff and amenities, and often prolong the drug development process.

Recent Developments in the Laboratory Animal Medicine Market

• In November 2025, Zoetis Inc. announced the acquisition of Veterinary Pathology Group (VPG), a foremost veterinary diagnostic laboratory group with multiple locations in Ireland and the UK. The acquisition also expands Zoetis’ comprehensive diagnostics selection and reinforces its commitment to progressing animal health via innovative and high-quality diagnostic solutions.
• In June 2025, Novartis announced that it completed its acquisition of Regulus Therapeutics Inc. By the completion of the acquisition, shares of common stock, par value $0.001 per share, of Regulus ceased trading on the Nasdaq Stock Market LLC, and Regulus is nowadays an indirect, exclusively owned subsidiary of Novartis

Segments Covered in the Report

By Animal Type

• Rodents 
  
  • Mice 
    
    • Transgenic Mice
    • Knockout Mice
    • Humanized Mice
  • Rats 
    
    • Inbred Rats
    • Outbred Rats
• Rabbits 
• Guinea Pigs 
• Hamsters 
• Non-Human Primates 
  
  • Cynomolgus Monkeys 
  • Rhesus Monkeys 
  • Marmosets 
• Dogs 
  
  • Beagle 
  • Other Breeds 
• Pigs 
  
  • Mini Pigs 
  • Conventional Pigs 
• Other Laboratory Animals 
  
  • Zebrafish 
  • Ferrets 
  • Bird

By Product

• Pharmaceuticals 
  
  • Analgesics 
  • Antibiotics 
  • Anesthetics 
  • Anti-inflammatory Drugs 
  • Parasiticides 
• Vaccines 
  
  • Viral Vaccines 
  • Bacterial Vaccines 
• Feed & Nutrition 
  
  • Standard Diets 
  • Specialized Diets 
• Diagnostic Kits 
  
  • Infectious Disease Kits 
  • Genetic Testing Kits 
• Bedding & Enrichment Products 
• Other Consumables 

By Service

• Veterinary Care Services 
  
  • Preventive Care 
  • Disease Management 
  • Surgical Support 
• Diagnostic Services 
  
  • Pathology 
  • Microbiology 
  • Molecular Diagnostics 
• Breeding Services 
• Quarantine & Biosecurity Services 
• Training & Consulting Services 

By Application

• Drug Discovery & Development 
  
  • Preclinical Research 
  • Toxicology Studies 
• Biomedical Research 
  
  • Oncology Research 
  • Immunology Research 
  • Neuroscience Research 
• Vaccine Development 
• Genetic Research 
• Academic Research 
• Other Applications 

By End User

• Pharmaceutical & Biotechnology Companies 
• Contract Research Organizations (CROs) 
• Academic & Research Institutes 
• Government Research Organizations 
• Veterinary Research Centers 

By Region

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait